Stock DNA
Pharmaceuticals & Biotechnology
SEK 193 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.32
-12.83%
2.60
Revenue and Profits:
Net Sales:
13 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.7%
0%
13.7%
6 Months
-11.65%
0%
-11.65%
1 Year
-31.01%
0%
-31.01%
2 Years
-42.88%
0%
-42.88%
3 Years
-17.03%
0%
-17.03%
4 Years
-61.86%
0%
-61.86%
5 Years
-62.1%
0%
-62.1%
SenzaGen AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
84.20%
EBIT Growth (5y)
10.92%
EBIT to Interest (avg)
-21.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.63
Tax Ratio
2.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.32
EV to EBIT
-11.60
EV to EBITDA
-37.28
EV to Capital Employed
3.10
EV to Sales
2.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.74%
ROE (Latest)
-12.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
57.70
49.90
15.63%
Operating Profit (PBDIT) excl Other Income
-4.00
-6.60
39.39%
Interest
0.50
0.30
66.67%
Exceptional Items
-8.30
-7.50
-10.67%
Consolidate Net Profit
-17.90
-22.10
19.00%
Operating Profit Margin (Excl OI)
-222.00%
-295.60%
7.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 15.63% vs 19.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 19.00% vs 11.24% in Dec 2023
About SenzaGen AB 
SenzaGen AB
Pharmaceuticals & Biotechnology
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Company Coordinates 
Company Details
Medicon Village, Building 401, Scheelevagen 2 LUND None : 223 63
Registrar Details






